Avid Bioservices Inc (CDMO)

[itsabouttime]

Ad HOC blood analysis was the MOA designed to determine effective treatment regimes for those that meet the criteria of the bio-markers. This procedure was certainly embedded in the Sunrise trial as mentioned in the PR and stated below. Let's see if anymore bio-markers emerge.


Treatments could be more effective in other indications.




The FDA certainly knew before hand what Peregrines intentions were and the FDA is on a new path to shorten trials, reduce patients in trials as much as possible, increase safety and efficacy and it looks like the FDA has a perfect opportunity here to do all that with PS Targeting biomarkers that allows a blood test to check for a biomarker that would help 30% of all lung cancer patients, just for starters till betabodies comes online and sounds like CP will be correct .